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Cancer immunotherapy has fundamentally changed the landscape of oncology in recent years 2 
and significant resources are invested into immunotherapy research. It is in the interests of re-3 
searchers and clinicians to identify promising and less promising trends in this field in order to 4 
rationally allocate resources. This requires a quantitative large-scale analysis of cancer immuno-5 
therapy related databases.  6 
We developed a novel tool for text mining, statistical analysis and data visualization of scientific 7 
literature data. We used this tool to analyze 72002 cancer immunotherapy publications and 8 
1469 clinical trials from public databases. All source codes are available under an open access 9 
license.  10 
The contribution of specific topics within the cancer immunotherapy field has markedly shifted 11 
over the years. We show that the focus is moving from cell-based therapy and vaccination to-12 
wards checkpoint inhibitors, with these trends reaching statistical significance. Rapidly growing 13 
subfields include the combination of chemotherapy with checkpoint blockade. Translational 14 
studies have shifted from hematological and skin neoplasms to gastrointestinal and lung cancer 15 
and from tumor antigens and angiogenesis to tumor stroma and apoptosis. 16 
This work highlights the importance of unbiased large-scale database mining to assess trends in 17 
cancer research and cancer immunotherapy in particular. Researchers, clinicians and funding 18 
agencies should be aware of quantitative trends in the immunotherapy field, allocate resources 19 
to the most promising areas and find new approaches for currently immature topics. 20 
 21 
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Cancer immunotherapy is widely regarded as one of the most promising approaches for treat-25 
ing metastatic cancer.1 It has been in the focus of basic, translational and clinical research for 26 
years and significant resources have been invested in finding new immunotherapy treatments 27 
with clinical efficacy.  28 
Anecdotally, most clinicians and researchers in the field are aware that clinical translation has 29 
not been equally successful for each subfield over the last years. For example, it is well-known 30 
that therapeutic vaccines were intensely investigated and shaped immunotherapy for years but 31 
have not yet made a direct clinical impact. Also, immunotherapy quickly reached clinical appli-32 
cation in melanoma2, while gastrointestinal cancer types are still lagging behind.3 These shifts 33 
within the cancer immunotherapy field are highly relevant for clinicians, researchers and fund-34 
ing agencies. However, until now, these changes have not been quantified in a way that allows 35 
an unbiased assessment of past and possible future trends.  36 
In the present study, we quantified the development of the cancer immunotherapy field from 37 
1986 to 2017 to reveal previously hidden trends. This type of quantitative and unbiased analysis 38 
is of high interest to researchers and clinicians because it can guide the allocation of resources 39 
for future research and clinical trials. Specifically, we focused on the comparison of treatment 40 
approaches, translational research topics and different tumor entities (organ of the primary 41 
tumor, according to the International Statistical Classification of Diseases and Related Health 42 
Problems, ICD-10). Among various types of cancer immunotherapy4, we looked at the devel-43 
opment of oncolytic viruses5, cell-based therapies6, therapeutic vaccines7, checkpoint inhibi-44 
tors8, 9 as well as chemotherapy and radiation therapy. These treatment types were separately 45 
analyzed for all tumor entities in order find out which approaches would be most promising in 46 
specific entities in the future. To quantify developments in basic and translational cancer re-47 
search, we included a wide range of topics such as the combination of immunotherapy with 48 
stroma 10 and cancer-associated fibroblasts11, angiogenesis12, tumor-specific antigens13, neoan-49 
tigens14, microbiota15, drug resistance16, myeloid cells17, stem cells18, epigenetics19, cell death 50 
and autophagy20, 21 as well as metabolism22. All trends were analyzed over time, keeping in 51 
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mind that the field was profoundly changed by landmark events such as the first clinical report 52 
of effective checkpoint inhibition in cancer patients in 2003.23, 24 Inhibitors of immune receptors 53 
and ligands are currently the largest class of approved immunotherapy drugs.25, 26 To investi-54 
gate this subfield in detail, we used a graph-based approach to visualize which of these check-55 
point pathways was in the focus of research efforts during the last years. Also, this analysis was 56 
used to identify promising combination approaches to target checkpoint signaling pathways. 57 
In short, we present a novel method for data collection, analysis and visualization of changing 58 
trends in cancer immunotherapy from 1986 to 2017 and discuss their implications. 59 
Methods 60 
Database queries 61 
Based on previous literature reviews and other publicly available resources, we manually curat-62 
ed a list of keywords to enable the comparison of different tumor entities (organ of the primary 63 
tumor, e.g. brain, breast, sarcoma, etc., complete list in Suppl. Table 1), treatment approaches 64 
(e.g. adoptive cell transfer, oncolytic viruses, checkpoint inhibition, etc., complete list in Suppl. 65 
Table 2), translational research topics (e.g. apoptosis, stem cells, epigenetics, etc., complete list 66 
in Suppl. Table 3) and cell types (e.g. myeloid, lymphoid, etc., complete list in Suppl. Table 4). 67 
Resources for therapeutic agents were the “NIH: A to Z List of Cancer Drugs” (retrieved from 68 
https://www.cancer.gov/about-cancer/treatment/drugs on 11 Nov 2017) and all FDA approvals 69 
2016 and 2017 (retrieved from 70 
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm on 11 Nov 71 
2017). Publication data were automatically mined from MEDLINE, the database of the United 72 
States National Library of Medicine (NLM), and its related search engine PubMed 73 
(https://pubmed.gov). Furthermore, we analyzed all cancer immunotherapy clinical trials regis-74 
tered in the official US (https://clinicaltrials.gov) database. PubMed articles were identified by 75 
the following master search keyword: ("tumor"[All Fields] OR "tumor"[All Fields] OR "neo-76 
plasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields]) AND ("immunothera-77 
py"[MeSH Terms] OR "immunotherapy"[All Fields]), in a similar way to a previously published 78 
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study.27 For clinical trials, the master keyword was: “cancer immunotherapy”. For clinical trials, 79 
all accessible trial metadata (title, description and structured information) was downloaded 80 
from respective databases. All database queries were made in November 2017. 81 
Data analysis  82 
All data analyzes and visualizations were conducted with self-developed MATLAB scripts 83 
(R2017a, MathWorks, Natick, MA, USA). Data were normalized to the number of total immuno-84 
therapy articles (or trials, respectively) in each year. Data points were smoothed with a moving 85 
average filter (lowpass filter with a coefficient equal to the reciprocal of the time span and a 86 
window size of five years). All scripts are released open-source and are available in: [DOI will be 87 
inserted after acceptance]. 88 
Trumpet plot 89 
To illustrate the temporal variation of the incidence of keyword groups, we used the self-90 
developed “trumpet plot”. Normalized and smoothed timelines were visualized as the height of 91 
a “trumpet” shape in a 2D. In 3D, the diameter of a cylinder represented the normalized num-92 
ber of research items in a given year with time as the vertical axis. Perceptually optimized col-93 
our scales from the “Color Brewer” project were used to visualize data.28 94 
Graph-based analysis and network plot 95 
To investigate the degree of connectivity between similar keywords in a specific subfield, we 96 
used a graph-based analysis. This was employed for keywords that represented different im-97 
mune checkpoint molecules e.g. PD-1, PD-L1, CTLA-4, CD80, etc. (full list in Suppl. Table 1). Each 98 
keyword was represented by a node which was visualized as a circle. The size and color of the 99 
circle depicted the number of research items matching this keyword. The distance between the 100 
node and the width of the connecting edge represented the co-occurrence of two keywords. 101 
Logarithmic scaling was used for the circle size and the edge width. Isolated nodes without any 102 
connection to other nodes were discarded. Low-abundant nodes (< 10 hits) and edges were al-103 




Shift from vaccination to checkpoint inhibition in clinical and translational studies 106 
First, we analyzed the contribution of major treatment types to the cancer immunotherapy lit-107 
erature. In the PubMed database, chemotherapy was the most frequent treatment that articles 108 
could be matched to (33% in 2017, Figure 1A). Checkpoint inhibition grew significantly (indicat-109 
ed by a + in the graphs) from 2015 and was the second most abundant treatment type in 2017. 110 
Therapeutic vaccination as a form of cancer immunotherapy dropped from position 1 to posi-111 
tion 3 in 2017, with significant decrease (indicated by a diamond in the graphs) between 2015 112 
and 2017. These trends were even more pronounced in clinical trials where checkpoint inhibi-113 
tion was matched in more than 50% of all items in 2017, chemotherapy being second with 26% 114 
and vaccination steadily dropping to only 9% of clinical trials in 2017 (Figure 2A). Adoptive cell-115 
based therapies (including chimeric antigen receptor [CAR] T-cells) contributed to 15% of all 116 
research items in 2017 and to 7% of all clinical trials (Figure 1A and Figure 2A). 117 
Lung and gastrointestinal cancer as prime targets for immunotherapy 118 
Next, we analyzed cancer immunotherapy research efforts for each tumor entity. In articles in-119 
dexed in PubMed, hematological neoplasias (hema.) were the prime immunotherapy target un-120 
til 2015/2016, but has decreased significantly since, yielding to skin and gastrointestinal (GI) 121 
neoplasms (Figure 1B). Among the top five tumor entities (skin, GI, hema., respiratory-thoracic 122 
[lung] and urinary tract), only lung and GI showed a significant growth in the last five years 123 
(Figure 1B). This pattern matched clinical trial data (Figure 2B) where lung and GI tumors were 124 
the top two cancer entities by far. Again, hematological neoplasms rapidly (and in one year sig-125 
nificantly) decreased in importance; also, sarcoma continuously decreased in importance over 126 
the years (Figure 2B). 127 
Subsequently, we asked how the different therapy approaches were reflected in each major 128 
tumor entity. In the research literature, checkpoint inhibitors have increased in importance in 129 
the last five years in all top five tumor entities (Figure 1D). The reverse trend can be observed in 130 
vaccination and chemotherapy, although these still have a large presence. Much more pro-131 
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nounced effects were observed in clinical trials (Figure 2D): Here, lung and GI neoplasms were 132 
the two most dynamically growing field with growth in skin cancer reaching a plateau and he-133 
matological neoplasms vanishing almost completely. 134 
A transient 1990s interest in myeloid cells left no trace in the clinic 135 
Cancer immunotherapy aims to (re)invigorate the host immune response against malignant 136 
cells and all types of cancer immunotherapy use cells in the tumor microenvironment as their 137 
effectors. We analyzed the quantitative contribution of cell types in the immunotherapy litera-138 
ture. Items related to myeloid cells significantly increased its presence in PubMed in the late 139 
1990s (Figure 1C), matching a large contribution to clinical trials at that time (Figure 2C). How-140 
ever, this transient interest in myeloid cells plateaued in the scientific literature and rapidly de-141 
creased in clinical trials. Not surprisingly, lymphoid cells were the largest single group of cells in 142 
2017 in scientific publications and clinical trials.  143 
Revival of radiation and chemo-immunotherapy 144 
Having analyzed major trends among treatment types, cancer types and cell types, we looked 145 
for non-obvious trends in the dataset. We found that among treatment types, radiation was 146 
only at position five in scientific articles (Figure 1A) but at position three in clinical trials (Figure 147 
2A). In both cases, the growth rate in 2017 significantly exceeded that of previous years. These 148 
trends followed a decrease during  the early 2000s in radiation therapy in articles and clinical 149 
trials (Figure 1A and Figure 2A). Based on these data, we conclude that we are currently wit-150 
nessing a revival of the use of radiation in cancer immunotherapy. 151 
We hypothesized that other non-obvious trends might be hidden in treatment combinations 152 
and therefore analyzed co-occurrence of treatment types in clinical trials (Figure 3A). In this 153 
analysis, the diagonal of the matrix corresponds to Figure 2A. We found that the only markedly 154 
increasing treatment combination is chemotherapy plus checkpoint inhibition (Figure 3A). In 155 
contrast, virtually no registered clinical trials investigate the combinations vaccination plus 156 
checkpoint inhibition or adoptive cellular therapy plus checkpoint inhibition.  157 
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Stroma and apoptosis in gastrointestinal cancer 158 
Our automatic approach for database mining allowed for an analysis of translational research 159 
topics per tumor type. For clarity, only a part of this analysis is shown in Figure 3B. We found 160 
that among translational research topics in immunotherapy articles, angiogenesis is decreasing 161 
in importance in all major cancer entities. In contrast, apoptosis (and other forms of cell death 162 
as well as autophagy) is rapidly gaining ground in GI, lung and skin cancer (Figure 3B). Interest-163 
ingly, the quantitative contribution of cancer stroma to immunotherapy articles is stagnating or 164 
decreasing in all major cancer entities except GI cancer (Figure 3B). Complementing our above-165 
described finding that GI cancer is one of the most dynamically growing research topics in im-166 
munotherapy, we conclude that especially apoptosis and stroma are promising subfields in this 167 
entity. 168 
Translational activities vary considerably between tumor types 169 
Our next step was to examine the following question: how were preclinical research efforts, 170 
measured by the number of indexed items on PubMed, translated into clinical trials? To give a 171 
specific answer for all therapy types and major cancer entities, we compared timelines for mul-172 
tiple keywords in PubMed and clinical trial databases. We analyzed the number of clinical trials 173 
in the last five years (2012-2016) and normalized these numbers to the respective number of 174 
PubMed research items in the preceding five years. Among all therapy types, immune check-175 
point inhibition stood out in terms of translational efficiency with close to 0.2 clinical trials per 176 
research paper in the reference periods (Figure 4A). Looking at various tumor entities, the dif-177 
ferences in translational efficiency were not as large (Figure 4B). Highest translational efficiency 178 
was visible in immunotherapy of gastrointestinal and respiratory neoplasms while a low transla-179 
tional efficiency was seen in hematological malignancies with just 0.02 clinical trials per article 180 
(Figure 4B).  181 
Another way of comparing the translational efficiency of immunotherapy subfields is to look at 182 
the development of clinical phase 1/2/3 trials over time. We matched all cancer immunothera-183 
py trials registered at clinicaltrials.gov and all PubMed articles (when applicable) to one or more 184 
clinical phases. In the timelines in Figure 5A, a small and stable percentage of PubMed articles 185 
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can be matched to any clinical trial phase over time. Within registered clinical trials (Figure 5B), 186 
phase 1 and 2 trials are slowly increasing with phase 3 trials decreasing at the same time. How-187 
ever, in general, no pronounced trends were visible in this analysis. This picture changed mark-188 
edly when analyzing clinical trials for each major tumor entity (Figure 5C): Phase 1 and 2 trials 189 
were rapidly increasing in gastrointestinal and lung cancer in the last five to ten years, but not 190 
in other major tumor entities. These data match our above-mentioned finding that GI and lung 191 
cancer are the most translationally active fields as compared to skin cancer, hematological neo-192 
plasias and other major cancer types.   193 
Immune-checkpoint networks 194 
Based on above-described results we concluded that checkpoint inhibition makes the largest 195 
quantitative contribution to research papers and clinical trials in immunotherapy research and 196 
is also the most efficient subfield in terms of clinical translation. Therefore, we performed a 197 
more specific analysis and asked how the contribution and intertwining of immune checkpoint 198 
molecules and drugs developed over time. Based on our timeline analysis (Figure 1A) we esti-199 
mated that around 2011, the increase in checkpoint inhibition publications started. We there-200 
fore used the following time frames, 1986-2010 and 2011-2016, to compare co-occurrence of 201 
checkpoint molecules in PubMed articles. These comparisons are shown in Figure 6 as network 202 
plots. In 1986 to 2010, CD80 had the highest prevalence (Figure 6A) and a cluster around 203 
CD80/CD86/CD28/CD40L/CD40 dominated the immune checkpoint landscape in PubMed arti-204 
cles. In 2011 to 2016, a marked change was evident and PD-1/PD-L1, which were previously in 205 
the periphery of the network, and CTLA-4, which remained in the center, made by far the larg-206 
est contribution (Figure 6B). Interestingly, CD80 (B7-1) still occupied a central “hub” position, 207 
linking two distant parts of the network with each other. 208 
Discussion 209 
Tumor immunotherapy research is a dynamically evolving field and has undergone profound 210 
changes in the last three decades. While these developments might be implicitly known by re-211 
searchers who have been deeply involved in the field for a long time, they are probably not ap-212 
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parent to most clinicians and scientists who are now confronted with immunotherapy. Moreo-213 
ver, researchers and clinicians working in the field may have cognitive biases and therefore may 214 
not be aware of well and poorly performing subfields of immunotherapy research. In this paper, 215 
we presented a quantitative, objective and comprehensive analysis of the changes in tumor 216 
immunotherapy research over time which can serve as a rational basis for further discussions. 217 
Skin cancer (mainly melanoma) was the first tumor entity to have effective immunotherapy 218 
agents approved and is still in the focus of research papers. Yet, clinical trials now focus on gas-219 
trointestinal and respiratory cancers, two major disease classes associated with significant 220 
morbidity and mortality. Translational research means that new knowledge should be effective-221 
ly transferred to the clinic.29 Researchers pursuing translational research will therefore meet 222 
this aim more easily in an area where translation has been shown to be feasible. By extrapolat-223 
ing these current trends, translational research efforts would be most fruitful in gastrointestinal 224 
and respiratory cancer.  225 
As a word of caution, we should also acknowledge that many unexpected breakthroughs come 226 
from previously unnoticed areas in biomedical research. Also, not all ongoing research efforts 227 
might be reflected by PubMed publications or registered clinical trials. Yet, for the tedious pro-228 
cess of using research results from the laboratory to improve treatments in the clinic, a struc-229 
tured and objective projection of future trends can be very useful. Our data-driven analytics 230 
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Figure Legends 295 
Figure 1: Trends in PubMed publications from 1986 to 2017 by topic. This figure summarizes all 296 
PubMed listed cancer immunotherapy articles grouped by category. (A) Among all cancer im-297 
munotherapy articles published in 2017, 33% referred to one or more specific chemotherapy 298 
drugs (bottom shape). This proportion was roughly constant over three decades. Contrariwise, 299 
checkpoint inhibition was almost absent before 2010, showing an accelerating growth after-300 
wards. (B) Hematological neoplasms were the most commonly investigated immunotherapy 301 
target until 2014, when they were overtaken by gastrointestinal and skin neoplasms. (C) Among 302 
all major cell types in the tumor microenvironment, myeloid cells were rapidly gaining interest 303 
around the year 2000. Afterwards, no significant change whatsoever was observed. (D) Bivari-304 
ate analysis of treatment types versus cancer types in PubMed cancer immunotherapy publica-305 
tions. Checkpoint inhibition shows a markedly increasing trend (“trumpet”) in skin, respiratory, 306 
but also urinary tract and gastrointestinal cancer. (A-C) + significant rise of growth rate within 307 
one year (anomaly >95%), ◊ significant decrease of one-year growth rate (anomaly < 5%). 308 
 309 
Figure 2: Trends in clinical trials from 2000 to 2017 per topic. This figure summarizes all regis-310 
tered clinical trials of cancer immunotherapy grouped by category. (A) Immune checkpoint in-311 
hibition has rapidly become the most common therapy approach between 2010 and 2017. At 312 
the same time, vaccination approaches have greatly diminished, being subject to only 9% of 313 
clinical immunotherapy trials in 2017. (B) As in PubMed publications, hematological neoplasms 314 
have markedly lost ground, yielding to gastrointestinal and respiratory neoplasms in recent 315 
years. (C) Among all major cell types in the tumor microenvironment, myeloid cells were in the 316 
focus of research interest around 2000, diminishing afterwards and only being investigated in 317 
2% of immunotherapy clinical trials in 2017. (D) Bivariate plot of treatment types versus cancer 318 
types in cancer immunotherapy clinical trials. Checkpoint inhibition shows an increasing trend 319 
(“trumpet”) in respiratory and gastrointestinal cancer. (A-C) + significant rise of growth rate 320 
within one year (anomaly >95%), ◊ significant decrease of one-year growth rate (anomaly < 321 
5%). 322 
 323 
Figure 3: Emerging immunotherapy paradigms. (A) Co-occurrence of cancer immunotherapy 324 
treatment approaches in clinical trials between 2000 and 2017. On the diagonal, the develop-325 
ment of individual treatment approaches is shown with checkpoint inhibition displaying a rapid 326 
increase. Off the diagonal, treatment combinations are shown with chemotherapy and check-327 
point inhibition being the most common and rapidly growing combination. (B) This bivariate 328 
plot shows cancer immunotherapy trends grouped by translational research topics and major 329 
cancer types based on all PubMed publications between 1986 and 2017. Among signalling, 330 
stroma, apoptosis and angiogenesis, apoptosis is the most rapidly growing topic in all major 331 
cancer entities except hematological neoplasms. Stroma and signalling are most rapidly increas-332 




Figure 4: Translational efficiency. We asked how the number of research publications influ-335 
ences the number of clinical trials in subsequent years. To this end, we analyzed PubMed arti-336 
cles for specific fields in a five-year period (2006-2011) and evaluated the number of matching 337 
US-registered clinical trials in the following five years (2012-2016). This yields a measure of 338 
translational efficiency (clinical trials per research publication). (A) Among therapy types, im-339 
mune checkpoint inhibitors had the highest translational efficiency with approximately 0.2 trials 340 
per publication. Scientific findings in vaccination and cell-based therapy were not efficiently 341 
translated to the clinic. (B) Among major tumor entities, translational efficiency was highest for 342 
gastrointestinal tumors and lowest for hematological and lymphoid malignancies (hema.). It is 343 
in the interest of the research community to increase translational efficiency in these low-344 
performing fields.  345 
 346 
Figure 5: Clinical trial phases. This figure shows the development of clinical trials in phase 347 
1/2/3 over time. (A) PubMed articles matching any clinical phase. Only a fraction of PubMed 348 
listed articles can be matched to a clinical phase and the proportions between the phases have 349 
not changed significantly in the last 20 years. (B) Clinical trials matching any clinical phase, or-350 
dered by group size, from bottom to top: phase 2, phase 1, phase 3. Some trials could be 351 
matched to multiple phases so that the percentages in 2017 do not necessarily add up to 100%. 352 
Phase 2 trials are most abundant and phase 1 trials are slowly growing, albeit not significantly.  353 
(C) In stark contrast to the slow overall growth dynamic of clinical trials in the above panels, this 354 
panel shows marked changes in clinical trials per cancer entity over time. In gastrointestinal 355 
cancer and respiratory-thoracic cancers, phase 1 and 2 trials are currently showing pronounced 356 
increase. (A+B) + significant rise of growth rate within one year (anomaly >95%), ◊ significant 357 
decrease of one-year growth rate (anomaly < 5%).  358 
 359 
Figure 6: Graph-based analysis of immune checkpoints. In these graphs, the distance between 360 
two nodes denotes the co-occurrence while the color of the bubble denotes the frequency of 361 
occurrence (bubble sizes are log occurrence). (A) Before 2011, a cluster around 362 
CD80/CD86/CD40/CD28 dominated immune checkpoint research. (B) This has fundamentally 363 
changed since 2011: The field is now dominated by PD-1/PDL1, with CTLA-4 as a bystander. The 364 
number of relevant immune checkpoints has markedly increased. CD80 still occupies a central 365 
position in the network, linking the CD40/CD86/CD40L cluster with PD1/PD-L1/CTLA-4. TIM3 366 
and OX40 have also moved closer to the network’s core, indicating an increasing importance 367 
despite few absolute hits.  368 
 369 






